CDKN2A and metastatic neoplasm: The share of pathologically up-staged patients, i.e. with pathological proof of clinically occult metastatic disease, while not yielding statistical significance in our patient sample, tended to be lower for p16-positive patients compared to their p16-negative counterparts.